DALY 2-EU clinical trial information
Learn more about DALY 2-EUDALY II-USA clinical trial information
Learn more about DALY II-USADALY II-USA clinical trial
DALY II-USA clinical trial
The DALY II-USA clinical trial examines the efficacy of the investigational medicinal product zamtocabtagene autoleucel in patients suffering from DLBCL or B cell CNS lymphoma. To participate in this trial, you must have previously received 2 or more different treatment regimens.
- Age ≥ 18 years
- Male or female
- Patients diagnosed with DLBCL or associated subtype, or with B cell primary or secondary CNS lymphoma.
- Patients who received at least two previous therapies to treat their disease for DLBCL without CNS involvement or at least one prior therapy line for patients with CNS lymphoma.
- Consenting to participate in this clinical trial.
If you participate in this trial, you will be assessed to confirm your eligibility. There are more criteria for you to participate. For further information, please contact your doctor or the doctor at the CAR-T cell center.
You should discuss with your doctor if participating in the DALY II-USA clinical trial is right for you.
- Access to a novel therapy that is not publicly available
- Regular appointments with medical professionals
- Playing an important role in the development of a therapy.
DALY II-USA clinical trial locations
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Arizona
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
California
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Connecticut
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Florida
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Illinois
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Kansas
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Maryland
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Massachusetts
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Michigan
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Minnesota
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
New York
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
North Carolina
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Ohio
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Oregon
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Pennsylvania
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Texas
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Wisconsin
We are regularly including new clinical trial sites in the USA. Please visit NCT04792489 to find your closest clinical trial site.
Glossary
Both primary and secondary B cell CNS lymphomas are rare subsets of B cell non-Hodgkin’s lymphoma.
T cells are part of the immune system that protects against diseases. CAR-T cells are altered T cells to fight cancer.
CAR-T cell center is a unit of a hospital specialized in CAR-T cell treatment.
DLBCL is an aggressive cancer of B cells. It is the most common form of non-Hodgkin lymphoma.
An investigational medicinal product is a pharmaceutical form of an active substance being tested in a clinical trial.
B cell central nervous system lymphoma (CNS) lymphoma
Both primary and secondary B cell CNS lymphomas are rare subsets of B cell non-Hodgkin’s lymphoma.
Investigational medicinal product
Investigational medicinal product is a pharmaceutical form of an active substance being tested in a clinical trial.
Diffuse large B cell lymphoma (DLBCL)
DLBCL is an aggressive cancer of B cells. It is the most common form of non-Hodgkin lymphoma.
Leukapheresis
Leukapheresis is a procedure where specific blood cells are collected from the patient’s blood for CAR-T cell manufacturing.
Lymphodepletion
Lymphodepletion is a treatment using chemotherapeutic drugs to prepare the patient for a CAR-T cell therapy.
CAR-T cell center
CAR-T cell center is a unit of a hospital specialized in CAR-T cell treatment.
CAR-T cells
T cells are part of the immune system that protects against diseases. CAR-T cells are altered T cells to fight cancer.
Neurological toxicity
Neurological toxicity is the presence of at least one neurological symptom appearing after CAR-T cell infusion. Their clinical spectrum is very heterogeneous.
Cytokine Release Syndrome
Cytokine Release Syndrome is a collection of symptoms that can develop as a side effect of CAR-T- cell therapy. The syndrome occurs when immune cells are activated and release large amounts of cytokines (inflammatory components) into the body.